


Supplementary figure 1: PTC-028 did not alter B cell, lymphocytes or total cellularity in the spleen on bone marrow.

 $Lyn^{-/-}$  mice were treated with vehicle control or PTC-028 and assessed on d15. (a) Frequency of splenic B cells as a proportion of total lymphocytes; (b) total number of splenic B cells; (c) total number of lymphocytes in the spleen; (d) total number of splenocytes. (e) Frequency of bone marrow B cells as a proportion of total lymphocytes; (f) total number of bone marrow B cell; (g) total number of lymphocytes in the bone marrow; (h) total number of bone marrow cells. Data are presented as the mean  $\pm$  SEM with individual data points representing one mouse. Data are combined from three independent experiments. n = 11 or 12 per group. Mann-Whitney nonparametric two-tailed tests were used for statistical analysis.

## Supplementary figure 2



Supplementary figure 2: Assessment of serum antibody in *Lyn*-/- mice and age-matched wild type mice.

(a) IgG1, (b) IgG2b, (c) IgG2c, (d) IgA and (e) IgM in  $Lyn^{-/-}$  mice treated with vehicle control or PTC-028 once daily on days 0 to 11 and then assessed on day 15. Data shown are representative of three independent experiments. n = 6 per group. Data is presented as the mean  $\pm$  SEM with individual data points representing one mouse. (f) ELISA results measuring total serum IgG3 antibody from wild-type mice ( $\geq$  6 months old) on day 15. Data shown are representative of two independent experiments. n = 5 per group. (g) Representative flow plots of FVS780<sup>-</sup>CD27<sup>hi</sup>CD38<sup>hi</sup> ASCs (previously gated on CD20<sup>-</sup>CD3<sup>-</sup>CD14<sup>-</sup>CD16<sup>-</sup>CD19<sup>+</sup>). Data are presented as the mean  $\pm$  SEM. Mann-Whitney nonparametric two-tailed tests were used for statistical analysis. \* $P \leq 0.05$ , \*\* $P \leq 0.01$ .

Supplementary table 1: Sjögren's Syndrome patient details.

Code ID	Sex	Age	Year of diag- nosis	Sjogren's manifestations	Comorbidities	Anti- SSA	RF	Serum IgG (g/L, NR 6-16)	ESSDAI score	Medication Immunomodulatory therapy in italics
SS01	F	32	2018	Sicca Salivary gland enlargement Annular erythema Lymphopenia	Pituitary microadenoma Autoimmune hypothyroidism	Yes	Yes	16.75	3	Prednisolone 3mg Hydroxychloroquine
SS02	F	60	2019	Sicca Inflammatory arthritis	Colonic adenocarcinoma Malignant melanoma	Yes	Yes	14.29	2	Meloxicam Thyroxine Propranolol Eletriptan Rosuvastatin Topiramate
SS03	F	61	2019	Sicca Salivary gland enlargement	Thyroid carcinoma Parotid gland mucoepidermoid carcinoma Type 2 diabetes mellitus Diabetic peripheral neuropathy	Yes	Not done	10.78	2	Sitagliptin Metformin Thyroxine Rosuvastatin Calcium carbonate and magnesium carbonate
SS04	F	62	2017	Sicca Lymphocytic interstitial pneumonitis	Obstructive sleep apnoea Hypertension Autoimmune hypothyroidism	Yes	Yes	24.04	26	Hydroxychloroquine Thyroxine Olmesartan Diclofenac Epomeprazole

				Cutaneous lupus erythematosus Inflammatory arthritis Lymphopenia						Paracetamol Nocturnal oxygen
SS05	F	62	2017	Sicca Peripheral and autonomic neuropathy Lymphopenia	Colonic carcinoma Hypertension Type 2 diabetes mellitus Exocrine pancreatic insufficiency	Yes	Yes	8.4	13	IVIg Hydroxychloroquine Amphotericin Amgapre Ondansetron Tramadol Paracetamol Atorvastatin Esomeprazole Lercanidipine Metformin Telmisartan/hydrochl orothiazide Carbamazepine
SS06	F	67	1995	Sicca Salivary gland enlargement Lymphadenopathy Splenomegaly Cutaneous vasculitis Lymphocytic interstitial pneumonitis		Yes	Yes	10.8	25	Prednisolone 10mg Mycophenolate mofetil Rituximab

Inflammatory			
arthritis			
Anaemia			

Supplementary table 2: Age and sex matched healthy donor details.

Code ID	Sex	Age	Patient match
HD01	Female	33	SS01
HD02	Female	61	SS02
HD03	Female	60	SS03
HD04	Female	64	SS04
HD05	Female	63	SS05
HD06	Female	67	SS06